Safety and Tolerability of Perampanel in Cervical Dystonia
Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
Cervical dystonia (CD) is the most common focal dystonia. Currently there are no effective
oral medications for the treatment of CD. While botulinum toxin injections improve symptoms,
they require repeated injections by a trained physician and some patients stop responding to
injections or never respond at all. Therefore, alternative treatment options for CD are
needed. One new agent is a drug that targets glutamate receptors that are thought to be
involved dystonia. This drug, perampanel, was originally developed for epilepsy and is
licensed for use in the USA and Canada for treating epilepsy. The purpose of this study is to
test the effectiveness of perampanel in treating the symptoms of CD.